347 related articles for article (PubMed ID: 28984761)
1. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Gao JH; Chu XC; Wang LL; Ning B; Zhao CX
Medicine (Baltimore); 2017 Oct; 96(40):e8059. PubMed ID: 28984761
[TBL] [Abstract][Full Text] [Related]
2. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Feng W; Wang X; Huang D; Lu A
Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
4. Preventive Effects of Different Drugs on Asymptomatic Lower Extremities Deep Venous Thrombosis After Artificial Joint Replacement: A Mixed Treatment Comparison.
Shao JB; Ni CF; Duan PF; Jin YH
Am J Ther; 2019; 26(1):e45-e53. PubMed ID: 26938762
[TBL] [Abstract][Full Text] [Related]
5. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
[TBL] [Abstract][Full Text] [Related]
6. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
8. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Suen K; Westh RN; Churilov L; Hardidge AJ
J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Morimoto T; Crawford B; Wada K; Ueda S
J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
12. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
13. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Squizzato A; Lussana F; Cattaneo M
Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
[TBL] [Abstract][Full Text] [Related]
14. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Wang Z; Zheng J; Zhao Y; Xiang Y; Chen X; Jin Y
Cell Physiol Biochem; 2017; 42(5):1999-2020. PubMed ID: 28793291
[TBL] [Abstract][Full Text] [Related]
16. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
[TBL] [Abstract][Full Text] [Related]
18. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
20. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
